Replies to post #4202 on Adamis Pharmaceuticals Corp (ADMP)

[Rollgard1]

Any research done on Paxlovid,Tempol etc....

shows Paxlovid had to enroll 1000's of patients in trial to establish Safety.Efficacy was second.Tempol already established the safety and prove its to the FDA by FDA allowing a small 248 patient study to get underway.That is what FDA said as to what was needed in their eyes.Not 1000's. Paxlovid was stopped too early and FDA knows it now.Probably regrets it do to the number of increasing rebounding cases.

It has EVERYTHING to do with being first and ahead of Tempol Trial. Being first does not make a drug better.See MERK as they were FIRST with theirs.Then came Paxlovid..Tempol will bring up the rear as it was the 3rd and last one standing for treating early covid symptoms.The other is late stage Covid for patients on any type of forced air.Just as MERK lost $$ to Paxlovid, Paxlovid will lose to Tempol if proven high enough efficacy and continued to show the stellar safety profile as to which it has shown for decades in many use(s) small trials. To say ADMP has a failing product line is not so.Symjepi has it's reasons and marketed in the USA only.Not worldwide.ZIMHI numbers represented last Q a small number of pre sales and not a full 90 day Quarter....

See last ADMP fling for verification on net 1.1 mil from ZIMHI sales and USWM kept 1.1 mil representing the 50/50 split is net profit per Agreement..Class dismissed.

Thanks Roll